The interplay between EGFR- and KRAS-mutant tumors and angiogenesis is reasonably well established: EGFR mutations have been linked to increased VEGF secretion in NSCLC cell lines, and multiple studies have found that KRAS contributes to the upregulation of VEGF and IL-8 in various cancers, essential for tumor angiogenesis [134]. Here, KRAS is linked to cancer.